Chief Executive Officer Ugur Sahin said new data would prompt a discussion about bringing the third shot of its currently available vaccine...

Lab tests are underway over the next two weeks to analyse the blood of people who had two or three doses of BioNTech's Comirnaty vaccine to...

The German biotech firm said that offering a third dose of its established two-shot vaccine remained the best response to concerns over wan...

A decision to make a switch should be made only if it is clear that the vaccine failed to work or is only offering sub-par protection again...

WHO's regional director said on Thursday COVID-19 vaccines being deployed in Europe, including that of Pfizer-BioNTech, appear able to prot...

Ugur Sahin, the chief executive of BioNTech, rejected the U.S.-backed proposal to temporarily lift some intellectual property rights for va...

The biotech company said the Singapore production facility will have an estimated annual capacity of several hundred million doses of mRNA-...

While the exact threshold required to reach that critical level of immunization remains a matter of debate, experts say a level above 70% w...

"We are still testing the Indian variant, but the Indian variant has mutations that we have already tested for and which our vaccine works ...

The encouraging results from an analysis of blood of participants in trials are based on more extensive analysis than those released by the...

The delays in rolling out the home-grown vaccine have caused consternation in Germany, where some regions had to halt vaccinations within d...

In a virtual press conference this week, Sahin spoke about the potential virus deadline when asked when life could return to normal.

"Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant," said Ugur Sahin.

Countries across the globe shut their borders to Britain on Monday due to fears about a highly infectious new coronavirus strain, causing t...

"The baseline plan is 1.3 billion doses," Sahin said. "And we are working on an extended plan. I can't tell you at the moment what is possi...

Pfizer and BioNTech are the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine. The compan...

Pfizer said on Monday said its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large s...